As of Wednesday close, Syndax Pharmaceuticals Inc.’s (NASDAQ:SNDX) stock was down -$0.51, moving down -2.33 percent to $21.39. The average number of shares traded per day over the past five days has been 1,044,520 shares. 4 times new highs have been achieved over the past 5 days, with a -$0.11 fall in that time frame. In the last twenty days, the average volume was 891,680, while in the previous 50 days, it was 895,252.
Since last month, SNDX stock rose 1.33%. Shares of the company fell to $19.55 on 05/04/23, the lowest level in the past month. A 52-week high of $29.86 was reached on 02/02/23 after having rallying from a 52-week low of $13.82. Since the beginning of this year, SNDX’s stock price has dropped by -15.95% or -$4.06, and marked a new high 7 times. However, the stock has declined by -28.37% since its 52-week high.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
SNDX stock investors should be aware that Syndax Pharmaceuticals Inc. (SNDX) stock had its last reported insider trading activity 16 days ago on May 09. Morrison Briggs, the Director of the company, disposed of 52,855 shares for $21.41 on May 09. It resulted in a $1,131,478 divestment by the insider. Morrison Briggs sold 52,855 shares at an average price of $19.53 on Apr 10. The insider now owns 17,836 shares following the transaction. On Mar 13, President, Head of R&D Morrison Briggs sold 52,854 shares at $22.53 apiece. The transaction was valued at $1,190,674.
In the three months ended March 30, Syndax Pharmaceuticals Inc.’s quick ratio stood at 18.60, while its current ratio was 18.60, showing that the company is able to pay off its debt. Based on annual data, SNDX earned $151.76 million in gross profit.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Syndax Pharmaceuticals Inc. to report -$0.6 quarterly earnings, the actual figure was -$0.59 per share, beating the consensus estimate by 1.70%. During the quarter, the company generated -$49.98 million in EBITDA. The liabilities of Syndax Pharmaceuticals Inc. were 24.32 million at the end of its most recent quarter ended March 30, and its total debt was $1.06 million. The value of shareholders’ equity is $68.82 million.
This quick technical analysis looks at Syndax Pharmaceuticals Inc.’s (SNDX) price momentum. With a historical volatility rate of 29.15%, the RSI 9-day stood at 52.44% on 24 May.
With respect to its five-day moving average, the current Syndax Pharmaceuticals Inc. price is down by -0.51% percent or -$0.11. At present, SNDX shares trade +2.79% above its 20-day simple moving average and -13.61% percent below its 100-day simple moving average. However, the stock is currently trading approximately -5.27% below its SMA50 and -11.90% below its SMA200.
Stochastic coefficient K was 62.57% and Stochastic coefficient D was 63.47%, while ATR was 0.94. Given the Stochastic reading of 46.55% for the 14-day period, the RSI (14) reading has been calculated as 52.04%. As of today, the MACD Oscillator reading stands at 0.37, while the 14-day reading stands at 0.70.
Syndax Pharmaceuticals Inc. (SNDX) has been rated Buy by analysts. According to 0 brokerage firms, SNDX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Syndax Pharmaceuticals Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $34.00, the current consensus forecast for the stock is $31.00 – $37.00. Based on these forecasts, analysts predict Syndax Pharmaceuticals Inc. (SNDX) will achieve an average price target of $33.78.